By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today announced a deal with Eli Lilly to develop a companion diagnostic for an investigational compound the drug manufacturer is developing for blood cancers.

The deal calls for Qiagen to develop, manufacture, and co-commercialize a test for Eli Lilly's JAK2 inhibitor, which targets the Janus kinase 2, or JAK2, gene, which is associated with myeloproliferative neoplasms, a variety of blood cancers that cause abnormal growth in blood cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.